Bob Klein is a San Francisco lawyer and housing developer whose teenage son has Type 1 diabetes. This man is giving his all for the cause of furthering stem cell research. He's profiled in today's SF Chronicle. It sounds like advocacy has essentially taken over his life: "He admits that his obsession with stem cells leaves scant time for home life these days, but insists the sacrifice will pay off if stem cell research can make some headway. 'I'd rather spend my time this way now than later on be spending time with (my son) in the hospital,' he said."

Thank you, Bob.

As a progressive thinker and diabetic, I find it

difficult to understand how people can oppose stem cell research on moral

grounds, when it has the potential to do so much good. Who or what are we protecting by blocking

this research, other than our own innate fear of change?

The US has fallen behind in stem cell research, due to the Bush Administration's push-back (see today's editorial in the Philadelphia Inquirer). Luckily, individual states have stepped up to the plate, with California in the lead at $3 billion over the next 10 years. But California's Proposition 71 for state-funded research is under attack, with two lawsuits in the works that "if successful could unravel the whole stem cell experiment." This is where Bob Klein comes in. He's fighting mad, and working hard. Support his cause here.

Meanwhile, U.S. BioDefense, Inc. is sponsoring the first "Business of Stem Cell Research" Conference to be held in Bethesda, Maryland, on April 25. This promises to be "the best resource for business people, academicians, scientists and the media to learn about the business of stem cell research in one-place-at-one-time." I'm just hoping they'll post the presentation content on the Web for us supporters in absentia.

Disclaimer: Content created by the Diabetes Mine team. For more details click here.


This content is created for Diabetes Mine, a consumer health blog focused on the diabetes community. The content is not medically reviewed and doesn't adhere to Healthline's editorial guidelines. For more information about Healthline's partnership with Diabetes Mine, please click here.